NRAS and neoplasm: Finally, we compared the plasma cfDNA levels in patients whose tumours presented with BRAF, NRAS or KIT mutations, and also in tumours that were wild type for all of the three genes, but did not find any correlation between plasma total cfDNA concentration and mutation group for these therapeutically important driver oncogenes (F value 1.4, 3 degrees of freedom [DF], P = 0.254) (Fig. 4A).